Skip to content

Effect of Sitagliptin on Plaques and Cardiac Function following ACS

Effect of Sitagliptin on Plaques and Cardiac Function following ACS - ESPECIAL-ACS

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000007900
Enrollment
46
Registered
2012-05-07
Start date
2012-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome end Type 2 Diabetes Mellitus

Interventions

Diet+ Exercise therapy and Sitagliptin 50-100mg/day Diet+ Exercise therapy

Sponsors

ESPECIAL-ACS office
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Patients with Acute coronary syndrome 2)Patients with coronary plaques (≥500micro m in thickness or 20% or more in % plaque) at ≥5mm from the previously treated area in the same branch of coronary artery. 3)Patients undergoing successful percutaneous coronary intervention (PCI) under IB-IVUS guidance to culprit lesion 4)Patients eating oral diet and drug within 72 hours 5)Patients with diabetes as defined by any of the following criteria: (1) NGSP HbA1c between 6.5% and 7.4% without diabetic drug; (2) NGSP HbA1c less than 7.4% using diabetic drug 6)Patients between 20 years and 80 years old at the time of their consent. 7)Patients giving written consent by their own volition after being provided sufficient explanation for participation in this clinical trial.

Exclusion criteria

Exclusion criteria: 1)diseased bypass graft 2)Patients who have plaque in a non-culprit site on the PCI vessel and might undergo PCI during the treatment period. 3)Patients receiving DPP4 inhibitor drugs and GLP-1 and high dose SU drugs at admission 4)Patients receiving more than 3 anti-diabetic drugs 5)Patients with acute congestive heart failure 6)Patients with ketoacidosis and diabetic coma within 6 months 7)Severe infection, Pre-operative and post-operative state, and severe trauma 8)Pregnant women, women suspected of being pregnant, or lactating women 9)Patients with severe renal disorders or undergoing dialysis 10)Patients with active malignant tumor 11)Patients with any allergy to DPP4 inhibitor 12)Patients who are ineligible in the opinion of the investigator.

Design outcomes

Primary

MeasureTime frame
percent change in coronary plaque volume

Countries

Japan

Contacts

Public ContactKatsumi Miyauchi

Juntendo University Cardiovascular Medicine

ktmmy@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026